Evidence map›Paper›PMID 35062327›Full record

ArticleViruses2022

Discriminatory Weight of SNPs in Spike SARS-CoV-2 Variants: A Technically Rapid, Unambiguous, and Bioinformatically Validated Laboratory Approach.

Nicolò Musso, Paolo Giuseppe Bonacci, Dafne Bongiorno, Stefano Stracquadanio, Dalida Angela Bivona, Concetta Ilenia Palermo, Guido Scalia, Marco Fichera, Stefania Stefani

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nicolò MussoDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.ORCID 0000-0003-2451-1158
Paolo Giuseppe BonacciDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.ORCID 0000-0002-7305-7433
Dafne BongiornoDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.ORCID 0000-0002-8672-0484
Stefano StracquadanioDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.
Dalida Angela BivonaDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.ORCID 0000-0002-2448-0227
Concetta Ilenia Palermo4U.O.C. Laboratory Analysis Unit, A.O.U. 'Policlinico-Vittorio Emanuele', University of Catania, 95125 Catania, Italy.
Guido Scalia4U.O.C. Laboratory Analysis Unit, A.O.U. 'Policlinico-Vittorio Emanuele', University of Catania, 95125 Catania, Italy.
Marco FicheraDepartment of Biomedical and Biotechnological Sciences, Medical Genetics, University of Catania, 95125 Catania, Italy.
Stefania StefaniDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMAR Lab), University of Catania, 95125 Catania, Italy.ORCID 0000-0003-1594-7427
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SARS-CoV-2 virus has assumed considerable importance during the COVID-19 pandemic. Its mutation rate is high, involving the spike (S) gene and thus there has been a rapid spread of new variants. Herein, we describe a rapid, easy, adaptable, and affordable workflow to uniquely identify all currently known variants through as few analyses. Our method only requires two conventional PCRs of the S gene and two Sanger sequencing reactions, and possibly another PCR/sequencing assay on a N gene portion to identify the B.1.160 lineage.

methodsWe selected an S gene 1312 bp portion containing a set of SNPs useful for discriminating all variants. Mathematical, statistical, and bioinformatic analyses demonstrated that our choice allowed us to identify all variants even without looking for all related mutations, as some of them are shared by different variants (e.g., N501Y is found in the Alpha, Beta, and Gamma variants) whereas others, that are more informative, are unique (e.g., A57 distinctive to the Alpha variant).

resultsA "weight" could be assigned to each mutation that may be present in the selected portion of the S gene. The method's robustness was confirmed by analyzing 80 SARS-CoV-2-positive samples.

conclusionsOur workflow identified the variants without the need for whole-genome sequencing and with greater reliability than with commercial kits.

Indexed as

Polymorphism, Single NucleotideClinical Laboratory TechniquesComputational BiologyCoronavirus Nucleocapsid ProteinsCOVID-19GenotypeHumansMutationPhosphoproteinsPolymerase Chain ReactionReproducibility of ResultsSARS-CoV-2Sequence Analysis, DNASpike Glycoprotein, CoronavirusWorkflowCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2bioinformatic validationCOVID-19COVID-19 variantsSanger sequencingSARS-CoV-2

Identifiers

PMID35062327
PMCPMC8781109
OpenAlexW4206183083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.